No Options Left: Inside CureMatch’s Fight to Personalize Cancer Care.

Traditional oncology has always relied on a trial-and-error approach when it comes to treatment, applying standard therapies to all patients. However, cancer is a disease that is fundamentally unique to every individual. So what happens when patients don’t respond to the standard course of treatment? When they are told there are no options left?

At CureMatch, co-founders Dr. Razelle Kurzrock and Navid Alipour refuse to accept this status quo when it comes to cancer care. These “cancer warriors” challenge the begrudging acceptance that standard medicine can run out of answers, and instead are pioneering a new perspective. One where human clinical expertise is intertwined with artificial intelligence to make each cancer treatment personalised for each patient. As Alipour shares, “We’re another arrow in their quiver in this fight against cancer to deliver better care and select optimal combinations earlier.”

The main challenge within modern oncology is no longer a lack of genomic testing, but an overwhelming abundance of complex data. Oncologists cannot afford the time to manually cross-reference thousands of genetic variants, drug combinations, and clinical trials for every single patient, thereby relying on standard courses of treatment.

But Dr Kurzrock refuses to abide by that practice, “because no two people’s cells are exactly the same, and cancer is caused by abnormalities in cells, it’s so important for each patient’s cancer treatment to be unique to their genetic makeup.” she explains.

That's where CureMatch comes in. They address this gap by creating a platform which can empower physicians to explore alternative courses of treatment. Complex genomic data is synthesized into a clear, ranked report of personalized treatment options, and as Alipour states “the human intelligence is married with the artificial intelligence.”

So, what’s the issue? CureMatch is now struggling to push back on the deeply unequal access to these treatment plans. For years, they have quietly provided clinical reports at no cost to pediatric cancer patients, operating on the conviction that personalized care should never depend solely on wealth or geography. However, as demand for precision care rises, small companies such as CureMatch face a growing burden in sustaining this support. Without intervention, vulnerable patients facing advanced or treatment-resistant cancers risk missing out on targeted therapies simply due to financial constraints.

To ensure no patient is left behind, CureMatch is launching a campaign to raise $500,000 to provide 500 cancer patients with access to its platform at no cost. A gift of $1,000 would sponsor one patient and their care team, allowing them to receive a comprehensive genomic report of their treatment plans. Alipour emphasizes “At the end of the day, we wake up every day saying if we could do one thing faster, it’s going to benefit someone’s life. That’s the urgency we’re driving towards every day.”

At the end of the day, real progress in cancer care requires a community that is willing to champion pioneers on the front lines. Behind every medical decision is a person, a family, and a future worth fighting for. Through its partnership with Music Beats Cancer, CureMatch is inviting donors, advocates, and families to join the movement to make precision medicine accessible to all, and to fight for the futures of patients who require personalised care.

This article was written in collaboration with Music Beats Cancer, a non-profit organization focused on fundraising for cancer research.